DelMar Pharmaceuticals Inc (NASDAQ:DMPI) has been assigned a consensus broker rating score of 1.50 (Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold rating and three have assigned a strong buy rating to the company.
Brokerages have set a 12 month consensus target price of $11.16 for the company and are anticipating that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also given DelMar Pharmaceuticals an industry rank of 181 out of 265 based on the ratings given to its competitors.
Separately, HC Wainwright set a $12.00 target price on shares of DelMar Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, October 16th.
An institutional investor recently bought a new position in DelMar Pharmaceuticals stock. Susquehanna International Group LLP bought a new position in shares of DelMar Pharmaceuticals Inc (NASDAQ:DMPI) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 364,496 shares of the company’s stock, valued at approximately $306,000. Susquehanna International Group LLP owned 1.69% of DelMar Pharmaceuticals at the end of the most recent quarter. 17.03% of the stock is owned by institutional investors.
DelMar Pharmaceuticals (DMPI) traded down $0.06 on Friday, hitting $1.23. 362,273 shares of the company were exchanged, compared to its average volume of 997,736. The stock has a market capitalization of $25.13, a P/E ratio of -1.81 and a beta of 1.14. DelMar Pharmaceuticals has a one year low of $0.78 and a one year high of $5.39.
DelMar Pharmaceuticals (NASDAQ:DMPI) last posted its quarterly earnings data on Monday, November 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). analysts forecast that DelMar Pharmaceuticals will post -0.54 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/10/zacks-analysts-set-11-16-price-target-for-delmar-pharmaceuticals-inc-dmpi.html.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.